查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1969241

心血管外科器械市场：按产品、技术、手术、最终用户和应用划分，全球预测，2026-2032年

Cardiovascular Surgery Devices Market by Product, Technology, Procedure, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，心血管外科器械市场价值将达到 587.4 亿美元，到 2026 年将成长至 631.4 亿美元，到 2032 年将达到 975.6 亿美元，复合年增长率为 7.51%。

主要市场统计数据
基准年 2025 587.4亿美元
预计年份：2026年 631.4亿美元
预测年份 2032 975.6亿美元
复合年增长率 (%) 7.51%

全面介绍由临床创新、营运重点和相关人员期望驱动的不断发展的心血管外科器械领域。

心血管外科器械市场环境的特征是临床创新快速、治疗路径不断演变，以及医疗系统和患者期望值不断提高。外科团队和采购经理如今需要在临床疗效和营运效率之间寻求平衡，并在此过程中重新定义器械性能、供应连续性和整体医疗成本的要求。因此，器械设计者、製造商和经销商面临着巨大的压力，他们必须提供能够无缝整合到多学科工作流程中，同时满足日益严格的安全性和循证医学标准的产品。

分析表明，临床、技术和商业性因素的整合正在重塑心血管外科医疗设备，并重新定义市场标准。

新的趋势正在改变心血管外科器械领域，加速医疗服务模式和器械设计方式的转变。随着微创手术和机器人辅助手术在适应症范围内日益受到青睐，器械製造商正致力于小型化、提高可视性以及增强器械与自动化平台的兼容性。同时，生物材料科学和胸骨缝合技术的创新正在改善患者的康復情况，而整合式灌注和氧合系统也在进行重新设计，以降低迴路复杂性并提高安全性。这些技术进步伴随着数位化集成，即时手术数据和互联设备为术中决策和术后追踪提供支援。

近期关税趋势如何促使医疗设备相关人员在采购、製造地、筹资策略和临床供应连续性方面进行策略性转变。

关税和贸易措施的推出可能会对整个心血管外科器械生态系统产生连锁反应，影响筹资策略、製造地和临床部署计画。零件和成品关税的提高可能会推高投入成本，迫使製造商决定是自行承担成本、转嫁给买家，还是调整价值链。这些选择可能会影响医院的采购行为，导致合约谈判更加严格、估值范围更广，并且更加关注整个生命週期成本，而不仅仅是单价。因此，医院和手术中心可能会修改其首选供应商名单，优先考虑能够提供本地生产能力和可预测交付条件的供应商。

基于对产品设计、临床环境、流程细微差别、技术方法和应用特性的深入细分，可以指导策略规划。

深入的市场区隔分析揭示了产品、最终用户、技术、流程和应用等清晰维度，从而指导市场参与企业的策略重点。在各个产品类型中，重点关注以下几点：插管分为动脉型、心臟麻痹和静脉型，对流体特性和生物相容性有严格的要求；心血管缝合线分为可吸收型和不可吸收型，评估其可操作性、结节强度和感染风险；心肺体外迴圈装置和氧合装置，其中气泡式和膜式氧合结构需要在便利性和血液相容性之间做出权衡；用于复杂解剖结构出血控制的液体/局部用止血剂；胸骨闭合装置，旨在实现复杂解剖结构的止血管理。在体外循环装置和氧合装置中，气泡式和膜式氧合系统的结构需要在便利性和血液相容性之间做出权衡。用于复杂解剖结构出血控制的止血剂有液体和局部用两种剂型。胸骨闭合装置有夹式和钢丝式两种类型，旨在优化机械稳定性并提高患者舒适度。血管移植物有生物来源和合成两种类型，兼顾了重塑潜力和长期耐久性。

区域间比较如何影响全球主要医疗保健区域的采用趋势、监管协调、商业模式和供应链策略。

区域趋势对技术采纳、监管路径和供应链结构有显着影响，每个宏观区域都为医疗设备相关人员带来了不同的机会和挑战。在美洲，先进的三级医疗中心和分散的社区医院并存，这不仅催生了对高度专业化的医疗设备的需求，也催生了对可扩展解决方案的需求，以支持在广泛的医疗网络中开展临时治疗。该地区的报销机制和医院集团采购惯例强调临床证据和可验证的疗效，鼓励供应商投资强大的临床伙伴关係和真实世界证据项目，以支持采购决策。

医疗设备製造商之间的策略竞争模式强调模组化创新、临床伙伴关係、增强型服务模式和有针对性的能力扩展。

心血管外科器材领域的竞争格局以技术差异化、策略联盟和重点临床证据项目为特征。领先的製造商优先发展模组化平台，以便在保持外科医生熟悉的符合人体工学操作的同时，实现组件级升级，从而降低过渡门槛。同时，多家公司正在拓展硬体以外的服务范围，他们意识到，包括培训项目、手术分析和售后支援在内的综合服务模式，有助于建立更牢固的客户关係，并创造持续的商机。医疗设备开发商与临床网路之间的合作日益策略化，从而能够联合开发新工具，并快速产生真实世界的临床证据，以支持医保报销谈判。

提供切实可行的策略指导，以平衡营运韧性、实证商业化和模组化产品创新，从而加速推广应用并降低风险。

产业领导者应采取多管齐下的策略，兼顾短期营运韧性和长期产品差异化。首先，透过采购多元化、考虑区域製造和合作製造协议，降低贸易中断风险，并提高前置作业时间可预测性。其次，优先采用模组化产品设计和平台策略，降低医院和手术中心的采用门槛，实现分阶段创新，无需全面更换手术器材库存。第三，投资产生严谨的临床证据，将手术结果与经济效益连结起来，从而向支付者和采购委员会清楚阐述价值主张。

为了获得可靠的见解，我们采用严格的混合研究方法，结合与专家的直接对话、整合二手证据和迭代检验。

本分析采用混合研究方法，结合了与主要相关人员的对话、针对性专家访谈以及对全面二手资讯的整合。主要资讯包括与临床负责人、采购经理、医疗设备工程师和监管专家的结构化对话，旨在了解医疗设备效能、应用障碍和采购趋势等方面的真实观点。二手研究整合了同行评审的临床文献、监管申报文件、产品标籤和器械标准，以支持技术和安全特性的论点。在整个分析过程中，我们运用了资料三角验证法，以协调不同的观点，并突显临床实务和供应链现实中的通用主题。

整合关键策略结论，重点阐述心血管外科器材领域临床创新、供应链韧性和实证商业化的交会点。

心血管外科器材领域正处于变革的关键时期，满足不断变化的医疗需求需要临床创新、供应链策略和实证商业化三者整合。微创手术和机器人辅助技术的进步，以及材料和灌注系统的改进，正在重新定义手术的可能性和临床医生的工作流程。同时，采购重点和监管压力要求供应商展现可衡量的价值，包括营运效率和可预测的供应，而不仅仅是器械性能。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 心血管外科器械市场：依产品划分

  • 套管
    • 动脉
    • 心臟麻痹药物
    • 静脉注射用
  • 心血管缝合
    • 吸收性
    • 不吸收
  • 体外循环机
  • 止血剂
    • 流动性
    • 本地使用
  • 人工肺
    • 气泡型
    • 电影
  • 胸骨闭合装置
    • 夹子
    • 线束系统
  • 血管移植
    • 生物起源
    • 合成

第九章：心血管外科器械市场：依技术划分

  • 传统手术
  • 微创手术
  • 机器人辅助手术

第十章：心血管外科器械市场：依手术类型划分

  • 主动脉手术
    • 动脉瘤修復手术
    • 分离修復
  • 先天性心臟疾病修復手术
  • 冠状动脉绕道手术手术
  • 瓣膜修復/置换术
    • 主动脉瓣
    • 二尖瓣
    • 三尖瓣

第十一章 心血管外科器械市场：依最终用户划分

  • 门诊手术中心
    • 医院所有
    • 独立
  • 诊所
    • 心臟病诊所
    • 一般诊所
  • 医院
    • 私人的
    • 民众

第十二章 心血管外科器械市场：依应用领域划分

  • 成人心臟手术
  • 儿童心臟外科手术

第十三章 心血管外科器械市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 心血管外科器械市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 心血管外科器械市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国：心血管外科器械市场

第十七章 中国：心血管外科器械市场

第十八章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Boston Scientific Corporation
  • Edwards Lifesciences Corporation
  • Getinge AB
  • Johnson & Johnson
  • LivaNova PLC
  • Medtronic PLC
  • Microport Scientific Corporation
  • Nihon Kohden Corporation
  • Qardio, Inc.
  • Schiller AG
  • Spandan
  • Terumo Corporation
  • Tricog Health, PTE Ltd
  • Vesalius Cardiovascular Inc.
  • Zoll Medical Corporation
Product Code: MRR-535C6291876B

The Cardiovascular Surgery Devices Market was valued at USD 58.74 billion in 2025 and is projected to grow to USD 63.14 billion in 2026, with a CAGR of 7.51%, reaching USD 97.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 58.74 billion
Estimated Year [2026] USD 63.14 billion
Forecast Year [2032] USD 97.56 billion
CAGR (%) 7.51%

A comprehensive orientation to the evolving cardiovascular surgery devices environment driven by clinical innovation, operational priorities, and stakeholder expectations

The landscape of cardiovascular surgery devices is defined by rapid clinical innovation, evolving care pathways, and heightened expectations from health systems and patients alike. Surgical teams and procurement executives are now balancing clinical outcomes with operational efficiency, and in doing so they are reshaping requirements for device performance, supply continuity, and total cost of care. As a result, device designers, manufacturers, and distributors are under pressure to deliver products that integrate seamlessly into multidisciplinary workflows while meeting stricter safety and evidence standards.

Moreover, the interplay of advanced biomaterials, digital monitoring, and automated systems is redefining what constitutes value in surgical devices. Clinicians increasingly demand devices that reduce procedural variability and shorten recovery times, while administrators prioritize solutions that enable predictable supply chain logistics and demonstrable reductions in downstream resource use. In this context, nuanced understanding of clinical pathways, reimbursement realities, and procurement dynamics is essential for stakeholders aiming to influence adoption and scale innovation. Consequently, the introduction frames the report's purpose: to synthesize technological, regulatory, and commercial drivers so that decision-makers can align product strategy with real-world clinical and operational imperatives.

An analysis of the converging clinical, technological, and commercial forces reshaping cardiovascular surgery devices and redefining market benchmarks

Emerging forces are transforming the cardiovascular surgery devices domain, and these changes are accelerating a shift in how care is delivered and how devices are designed. Minimally invasive and robotics-assisted approaches are increasingly preferred for suitable cases, prompting device makers to invest in smaller form factors, enhanced visualization, and instrument compatibility with automated platforms. Concurrently, biomaterials science and sternal closure innovations are enabling improved patient recovery profiles, while integrated perfusion and oxygenation systems are being reconceptualized to reduce circuit complexity and enhance safety. These technological advances are accompanied by digital integration, where real-time procedural data and connected devices support intraoperative decision-making and post-operative follow-up.

At the same time, health systems are emphasizing value-based outcomes, which shifts procurement conversations toward devices that demonstrate measurable reductions in complications, length of stay, and readmissions. This emphasis is driving greater collaboration among device developers, clinical leaders, and payers to generate robust clinical evidence and economic models. Moreover, supply chain resilience and regional manufacturing capacity are becoming strategic differentiators due to geopolitical dynamics, prompting companies to rethink sourcing and inventory strategies. In summary, the convergence of clinical innovation, data-enabled care, and commercial pressures is reconfiguring the competitive landscape and establishing new benchmarks for product development and market access.

How recent tariff developments are driving strategic shifts in sourcing, manufacturing footprints, procurement tactics, and clinical supply continuity across device stakeholders

The imposition of tariffs and trade measures can create cascading effects across the cardiovascular devices ecosystem, influencing procurement strategies, manufacturing footprints, and clinical adoption timelines. When tariffs increase input costs for components or finished devices, manufacturers face decisions about absorbing costs, passing them on to buyers, or adjusting supply chain arrangements. These choices affect hospital purchasing behavior and can prompt tighter contract negotiations, expanded value reviews, and a deeper focus on total lifecycle costs rather than unit price alone. In turn, hospitals and surgical centers may re-evaluate preferred vendor lists, favoring suppliers that can demonstrate local manufacturing capabilities or predictable delivery terms.

Consequently, procurement teams are likely to seek contractual protections and multi-sourcing approaches to mitigate exposure to sudden cost escalation. This means that suppliers with diversified manufacturing footprints or those able to nearshore production gain a competitive advantage in stability of supply. Furthermore, regulatory compliance and customs processes interact with tariffs to influence lead times and inventory planning; therefore, organizations are prioritizing supply chain transparency and demand forecasting. Clinically, any disruptions that cause device substitutions or delays can complicate scheduling and increase administrative burdens, reinforcing the need for robust clinical and operational contingency plans. Overall, tariffs act as a catalyst for long-term strategic shifts in sourcing, inventory management, and vendor relationships across the cardiovascular surgery devices sector.

Deep segmentation-driven insights across product design, clinical setting, procedural nuance, technological approach, and application specificity to guide strategy

Insightful segmentation analysis reveals distinct product, end-user, technological, procedural, and application dimensions that inform strategic priorities for market participants. Across product categories, attention centers on cannulas-categorized by arterial, cardioplegia, and venous types-which must meet stringent flow dynamics and biocompatibility requirements; cardiovascular sutures, differentiated into absorbable and nonabsorbable options, which are evaluated for handling, knot security, and infection risk; heart-lung machines and oxygenators, where bubble and membrane oxygenation architectures present trade-offs between simplicity and hemocompatibility; hemostats available in flowable and topical formats that address bleeding control in complex anatomies; sternal closure devices offered as clips or wiring systems designed to optimize mechanical stability and patient comfort; and vascular grafts in biological and synthetic variants that balance remodeling potential with long-term durability.

In parallel, end-user segmentation identifies ambulatories, clinics, and hospitals with differing purchasing behaviors and clinical requirements. Ambulatory surgical centers, whether hospital owned or independent, typically prioritize throughput and cost-efficiency and thus favor devices that shorten procedure and turnover times. Cardiac specialty clinics versus general clinics diverge in their need for specialized instrumentation and post-operative monitoring capabilities, whereas private and public hospitals each navigate budgetary constraints and procurement cycles that influence adoption. Technology segmentation highlights the trajectory from conventional open surgery to minimally invasive and robotics-assisted approaches, with implications for device form factors, instrumentation compatibility, and training needs. Procedurally, device requirements vary significantly across aortic surgery subtypes, congenital repairs, coronary artery bypass grafting, and valve repair or replacement-with specific device attributes tailored to aneurysm or dissection repair and to aortic, mitral, or tricuspid valve interventions. Finally, application segmentation between adult and pediatric cardiac surgery underscores the clinical differentiation in sizing, material selection, and regulatory pathways. Together, these segmentation lenses provide a layered framework for targeted product development, commercialization strategies, and clinical evidence generation.

Comparative regional dynamics shaping adoption, regulatory alignment, commercial models, and supply chain approaches across the principal global healthcare regions

Regional dynamics exert a strong influence on technology adoption, regulatory pathways, and supply chain architecture, and each macro-region presents distinct opportunities and challenges for device stakeholders. In the Americas, a mix of advanced tertiary centers and distributed community hospitals creates demand for both highly specialized devices and scalable solutions that support episodic procedures across broad networks. Reimbursement mechanisms and hospital group procurement practices in the region place a premium on clinical evidence and demonstrable outcomes, prompting suppliers to invest in robust clinical partnerships and real-world evidence programs to support purchase decisions.

Across Europe, the Middle East and Africa, diverse regulatory frameworks and variable healthcare funding models necessitate regionally adapted market entry and pricing strategies. While some European countries maintain centralized procurement processes and mature HTA (health technology assessment) pathways, other markets in the broader region require tailored clinical validation and localized value propositions to drive adoption. Meanwhile, in the Asia-Pacific region, rapid infrastructure investment and growing surgical volumes are accelerating uptake of minimally invasive and robotics-assisted technologies, supported by expanding manufacturing capabilities and a rising cohort of local innovators. However, stakeholders must navigate heterogeneous regulatory timelines and a strategic emphasis on localized production that can influence partnership models. In all regions, travel and training limitations, reimbursement heterogeneity, and supply chain resilience considerations are key determinants of success, and firms that adapt commercial models to regional healthcare incentives and ecosystem capabilities will position themselves to capture sustained clinical engagement.

Strategic competitive patterns emphasizing modular innovation, clinical partnerships, enhanced service models, and targeted capability expansion among device manufacturers

The competitive environment in the cardiovascular surgery devices arena is characterized by technological differentiation, strategic alliances, and focused clinical evidence programs. Leading manufacturers are prioritizing modular platforms that allow component-level upgrades while maintaining familiar surgeon ergonomics, thereby reducing switching friction. At the same time, several firms are expanding service offerings beyond hardware to include training programs, procedural analytics, and aftermarket support, recognizing that integrated service models strengthen customer relationships and create recurring revenue opportunities. Partnerships between device developers and clinical networks are becoming more strategic, enabling co-development of new tools and acceleration of real-world evidence generation that supports reimbursement discussions.

Moreover, mid-sized and emerging companies are leveraging niche expertise in biomaterials, sternal closure innovations, or specialty graft technologies to challenge incumbents on clinical performance or cost effectiveness. Mergers and acquisitions remain a tactical option for acquiring complementary capabilities or expanding geographic reach, while strategic manufacturing investments seek to mitigate trade-related disruptions and shorten lead times. Importantly, success increasingly depends on the ability to demonstrate clinically meaningful improvements observed in routine practice, so companies that invest in outcomes research, registries, and transparent post-market surveillance gain a competitive edge. Overall, the landscape favors organizations that combine engineering sophistication with robust clinical partnerships and adaptive commercial models.

Actionable strategic guidance for balancing operational resilience, evidence-driven commercialization, and modular product innovation to accelerate adoption and reduce risk

Industry leaders should adopt a multi-dimensional strategy that balances near-term operational resilience with long-term product differentiation. First, diversify sourcing and explore regional manufacturing or co-manufacturing agreements to reduce exposure to trade disruptions and to improve lead-time predictability. Second, prioritize modular product design and platform strategies that permit incremental innovation without requiring wholesale replacement of surgical inventories, thereby lowering adoption barriers for hospitals and surgical centers. Third, invest in rigorous clinical evidence generation that pairs procedural outcomes with economic endpoints so that value can be clearly articulated to payers and procurement committees.

Additionally, strengthen go-to-market capabilities by aligning surgeon education programs, simulation-based training, and digital procedural analytics to demonstrate real-world performance and facilitate adoption. Engage early and transparently with regulatory and HTA stakeholders to streamline approval pathways and build trust in novel device classes. Form targeted partnerships with specialty clinics, high-volume centers, and regional distributors to pilot innovations and scale proven approaches. Finally, integrate lifecycle services such as preventive maintenance, rapid spare-part logistics, and procedural support to create stickier customer relationships and predictable revenue streams. By executing on these recommendations, organizations can improve resilience to external shocks while reinforcing the clinical and economic value propositions essential for sustained adoption.

A rigorous mixed-methods research approach combining primary expert engagement, secondary evidence synthesis, and iterative validation to ensure robust insights

This analysis is grounded in a mixed-methods research approach that combines primary stakeholder engagement, targeted expert interviews, and comprehensive secondary-source synthesis. Primary inputs included structured conversations with clinical leaders, procurement executives, biomedical engineers, and regulatory specialists to capture real-world perspectives on device performance, adoption barriers, and procurement dynamics. Secondary research integrated peer-reviewed clinical literature, regulatory filings, product labeling, and device standards to corroborate technical and safety characteristics. Data triangulation was applied throughout to reconcile divergent perspectives and to surface consistent themes across clinical practice and supply chain realities.

Methodological rigor was further ensured through iterative expert validation sessions, in which preliminary findings were reviewed and refined with subject-matter experts to confirm clinical plausibility and commercial relevance. Segmentation was implemented across product, end-user, technology, procedure, and application dimensions to permit granular analysis while preserving cross-segment comparability. Limitations include variability in regional data transparency and the inherent lag between clinical adoption and published outcomes, and these were mitigated through contemporary expert input and scenario analysis. Finally, quality control processes were applied to ensure clarity, reproducibility, and defensibility of the insights presented.

A synthesis of critical strategic conclusions emphasizing the intersection of clinical innovation, supply chain resilience, and evidence-driven commercialization in cardiovascular surgery devices

The cardiovascular surgery devices sector is at an inflection point where clinical innovation, supply chain strategy, and evidence-based commercialization must converge to meet evolving healthcare expectations. Technological advances in minimally invasive and robotics-assisted approaches, together with materials and perfusion system improvements, are redefining procedural possibilities and clinician workflows. Simultaneously, procurement priorities and regulatory pressures are pushing suppliers to demonstrate measurable value that extends beyond device performance to encompass operational efficiency and predictable supply.

In response, manufacturers and distributors must embrace integrated strategies that align product design with clinical realities, invest in authentic clinical evidence, and build resilient supply chains capable of absorbing geopolitical and trade-related disruptions. Those who adopt platform-based innovation, deepen clinical partnerships, and offer comprehensive service ecosystems will be best positioned to influence adoption curves and sustain commercial momentum. Ultimately, the ability to translate technical superiority into verifiable clinical and economic outcomes will determine which organizations lead the next wave of progress in cardiovascular surgical care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiovascular Surgery Devices Market, by Product

  • 8.1. Cannulas
    • 8.1.1. Arterial
    • 8.1.2. Cardioplegia
    • 8.1.3. Venous
  • 8.2. Cardiovascular Sutures
    • 8.2.1. Absorbable
    • 8.2.2. Nonabsorbable
  • 8.3. Heart Lung Machines
  • 8.4. Hemostats
    • 8.4.1. Flowable
    • 8.4.2. Topical
  • 8.5. Oxygenators
    • 8.5.1. Bubble
    • 8.5.2. Membrane
  • 8.6. Sternal Closure Devices
    • 8.6.1. Clips
    • 8.6.2. Wiring Systems
  • 8.7. Vascular Grafts
    • 8.7.1. Biological
    • 8.7.2. Synthetic

9. Cardiovascular Surgery Devices Market, by Technology

  • 9.1. Conventional Surgery
  • 9.2. Minimally Invasive Surgery
  • 9.3. Robotics Assisted Surgery

10. Cardiovascular Surgery Devices Market, by Procedure

  • 10.1. Aortic Surgery
    • 10.1.1. Aneurysm Repair
    • 10.1.2. Dissection Repair
  • 10.2. Congenital Heart Defect Repair
  • 10.3. Coronary Artery Bypass Grafting
  • 10.4. Valve Repair Replacement
    • 10.4.1. Aortic Valve
    • 10.4.2. Mitral Valve
    • 10.4.3. Tricuspid Valve

11. Cardiovascular Surgery Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
    • 11.1.1. Hospital Owned
    • 11.1.2. Independent
  • 11.2. Clinics
    • 11.2.1. Cardiac Specialty Clinics
    • 11.2.2. General Clinics
  • 11.3. Hospitals
    • 11.3.1. Private
    • 11.3.2. Public

12. Cardiovascular Surgery Devices Market, by Application

  • 12.1. Adult Cardiac Surgery
  • 12.2. Pediatric Cardiac Surgery

13. Cardiovascular Surgery Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cardiovascular Surgery Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cardiovascular Surgery Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cardiovascular Surgery Devices Market

17. China Cardiovascular Surgery Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. B. Braun Melsungen AG
  • 18.7. Baxter International Inc.
  • 18.8. Boston Scientific Corporation
  • 18.9. Edwards Lifesciences Corporation
  • 18.10. Getinge AB
  • 18.11. Johnson & Johnson
  • 18.12. LivaNova PLC
  • 18.13. Medtronic PLC
  • 18.14. Microport Scientific Corporation
  • 18.15. Nihon Kohden Corporation
  • 18.16. Qardio, Inc.
  • 18.17. Schiller AG
  • 18.18. Spandan
  • 18.19. Terumo Corporation
  • 18.20. Tricog Health, PTE Ltd
  • 18.21. Vesalius Cardiovascular Inc.
  • 18.22. Zoll Medical Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PROCEDURE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CANNULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CANNULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CANNULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CANNULAS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ARTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ARTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ARTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOPLEGIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOPLEGIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOPLEGIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOVASCULAR SUTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOVASCULAR SUTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOVASCULAR SUTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOVASCULAR SUTURES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ABSORBABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ABSORBABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ABSORBABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY NONABSORBABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY NONABSORBABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY NONABSORBABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEART LUNG MACHINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEART LUNG MACHINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEART LUNG MACHINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEMOSTATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEMOSTATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEMOSTATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY FLOWABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY FLOWABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY FLOWABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY OXYGENATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY OXYGENATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY OXYGENATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY BUBBLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY BUBBLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY BUBBLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY MEMBRANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY MEMBRANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY MEMBRANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY STERNAL CLOSURE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY STERNAL CLOSURE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY STERNAL CLOSURE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY STERNAL CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY WIRING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY WIRING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY WIRING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY BIOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY BIOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY BIOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CONVENTIONAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CONVENTIONAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CONVENTIONAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ROBOTICS ASSISTED SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ROBOTICS ASSISTED SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ROBOTICS ASSISTED SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ANEURYSM REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ANEURYSM REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ANEURYSM REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY DISSECTION REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY DISSECTION REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY DISSECTION REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CONGENITAL HEART DEFECT REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CONGENITAL HEART DEFECT REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CONGENITAL HEART DEFECT REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VALVE REPAIR REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VALVE REPAIR REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VALVE REPAIR REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VALVE REPAIR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY MITRAL VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY MITRAL VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY MITRAL VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TRICUSPID VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TRICUSPID VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TRICUSPID VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITAL OWNED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITAL OWNED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITAL OWNED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIAC SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIAC SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIAC SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ADULT CARDIAC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ADULT CARDIAC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY ADULT CARDIAC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PEDIATRIC CARDIAC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PEDIATRIC CARDIAC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PEDIATRIC CARDIAC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CANNULAS, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOVASCULAR SUTURES, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY STERNAL CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VALVE REPAIR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CANNULAS, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOVASCULAR SUTURES, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY STERNAL CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VALVE REPAIR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CANNULAS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOVASCULAR SUTURES, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY STERNAL CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VALVE REPAIR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CANNULAS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOVASCULAR SUTURES, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY STERNAL CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VALVE REPAIR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CANNULAS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOVASCULAR SUTURES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY STERNAL CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VALVE REPAIR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CANNULAS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOVASCULAR SUTURES, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY STERNAL CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VALVE REPAIR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CANNULAS, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOVASCULAR SUTURES, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY STERNAL CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VALVE REPAIR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CANNULAS, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOVASCULAR SUTURES, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY STERNAL CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VALVE REPAIR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. GLOBAL CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CANNULAS, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY CARDIOVASCULAR SUTURES, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY STERNAL CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN CARDIOVASCULAR SURGERY DEVICES MARKET SIZE, BY TECHNO